RXST SECURITIES NOTICE: Did RxSight, Inc. Mislead Investors? Contact BFA Law if You Lost Money on Your Investment

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - RxSight, Inc. specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its main product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Financial Performance and Issues - During the relevant period, RxSight promoted strong sales of its LAL and Light Delivery Device (LDD) but failed to disclose "adoption challenges" and a slowdown in LAL utilization that began in 2024 [4]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast due to a "softening" market, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - On July 8, 2025, the company further lowered its revenue forecast, attributing it to slower LAL utilization and adoption challenges, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [6].